Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (4252)	5/7/1998 10:17:00 AM
From: ALL	Read Replies (3) of 6136

Ralf, Keep in mind that gross margins for Viracept include European sales and costs, which tend to distort actual margins because AGPH sells Viracept to Roche for most international sales at cost + about 5% and receives royalties in turn. In the most recent quarter, US Viracept sales were $92.8 million and $19.2 million internationally. Adjusting for international sales, gross (US) margins were 66 to 67%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next